Merck & Company, Inc.
当前追踪的 33 家顶级对冲基金 2026 Q3 13F 申报中暂无重仓该标的记录
渗透率: 0.0%
-
💡 口径说明:变动幅度超过 ±0.5% 计为加仓增持/减仓减持,±0.5% 以内计为持仓不变;净增持占比 = (增持家数 + 新建仓家数) / 持仓机构总数。
基于 2026 Q3 SEC 13F 申报
🚀MRK SGDC 量化评级与战术档案
📌 核心业务与护城河简评:Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
截至 2026-11-18 收盘,股价处于 50SMA 均线下方修正期(收盘结算价 $137.78 < 50SMA $145.67),触发动量风控拦截。
📈近 8 个季度机构持股演变趋势
追踪该标的在过去 8 个季度中被全球顶尖百亿基金持有数量与平均权重的历史变迁
🏛️持有该股的顶级机构明细2026 Q3
查看 2026 Q3 重仓该股的每家对冲基金经理、持股数量、仓位权重与调仓动向
| 投资大佬 / 机构 | 基金管理规模 | 持仓权重 | 持有股数 | 季度动向 | 操作 |
|---|---|---|---|---|---|
| 当前暂无顶级对冲基金持有该标的 | |||||
想知道华尔街大佬们本期最抱团的前 50 只暗牌金股?
与其单只股票反查,不如直接在共识筛股器中获取 33 家对冲基金共同重仓的 Alpha 清单。